RNDr. Pavel Krejčí, Ph.D.
Head of the research group, Pavel Krejčí Research Group
office: bldg. A19/231a
Kamenice 753/5
625 00 Brno
| phone: | +420 549 49 5395 |
|---|---|
| e‑mail: |
| social and academic networks: |
|---|
Total number of publications: 133
2026
-
Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes
MOLECULAR BIOMEDICINE, year: 2026, volume: 7, edition: 1, DOI
-
Infigratinib is a weak inhibitor of the FGFR3-N540K mutant associated with hypochondroplasia
Journal of bone and mineral research, year: 2026, DOI
2025
-
Endoplasmic reticulum stress disrupts signaling via altered processing of transmembrane receptors
Cell Communication and Signaling, year: 2025, volume: 23, edition: 1, DOI
-
FGFR2 residence in primary cilia is necessary for epithelial cell signaling
Journal of cell biology, year: 2025, volume: 224, edition: 7, DOI
-
Increased thermal stability of FGF10 leads to ectopic signaling during development
Cellular and molecular life sciences, year: 2025, volume: 82, edition: 1, DOI
-
Oral Infigratinib Therapy in Children with Achondroplasia
New England journal of medicine, year: 2025, volume: 392, edition: 23, DOI
-
POLIPEPTÍDEO TERMOESTÁVEL E MEIO DE CULTURA
Publisher: Instituto Nacional da Propriedade Industrial, state: Brazil, patent's number: BR 112018010676-3, year: 2025
-
Protein structure and interactions elucidated with in-cell NMR for different cell cycle phases and in 3D human tissue models
Communications Biology, year: 2025, volume: 8, edition: 1, DOI
-
Specific inhibition of fibroblast growth factor receptor 1 signaling by a DNA aptamer
MOLECULAR THERAPY-NUCLEIC ACIDS, year: 2025, volume: 36, edition: 1, DOI
2024
-
Achondroplasia: aligning mouse model with human clinical studies shows crucial importance of immediate postnatal start of the therapy
Journal of bone and mineral research, year: 2024, volume: 39, edition: 12, DOI